ugn-103
Generic: mitomycin
ugn-103: sourced relationships with 1 company · 1 clinical trial tracked.
ugn-103 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect ugn-103 to URGN; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could ugn-103 → URGN affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| UroGen Pharma Ltd. (URGN) | Phase 3 |
Clinical Trial Registry Records (1)
A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel Formulation of UGN-102, for the Treatment of Patients With Low-grade (LG) Non-muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
Primary endpoint: Complete Response Rate (CRR)
Interventionalopen99 enrolledStarted 2024-08Completion 2026-0948 sites · Bulgaria, Estonia, Georgia, Latvia…UroGen Pharma Ltd.
Frequently asked questions
Which companies have sourced relationships with ugn-103?
ugn-103 has dated SEC/FDA relationship records for UroGen Pharma Ltd..
How many clinical trials involve ugn-103?
BioSniper tracks 1 clinical trial involving ugn-103.